Special Edition: What's Next—Oral GLP-1 Receptor AgonistsDiabetes Core UpdateIn this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide. This special episode is sponsored with support f...265 days agoSpecial Edition: What's Next—Oral GLP-1 Receptor AgonistsDiabetes Core Update0:00 / 0:00Read the original at diabetescoreupdate.libsyn.comUse this feed in your RSS readerCopy the publisher’s public feed URL, or build an OPML reading list for another reader.Copy RSS URL Open RSS feed · Find feeds & export OPMLKeep up with this sourceFollow this sourceKeep this source in your dashboard and return to its latest articles. Email alerts are managed separately in Settings.FetchFeeds groups articles by feed so you can follow sources, compare coverage, and save stories for later.Back to all articles from Diabetes Core UpdateMore from this feedChoose another story from Diabetes Core Update.The Points of CARE - Introducing Diabetes, Obesity, and CardioMetabolic CARE with Alissa Segal, the ADA's Obesity Association & Standards of Care in Overweight and Obesity with Samar Hafida, and more!Special Edition: What's Next—Understanding Chronic Kidney Disease in People with Diabetes—Epidemiology, Pathophysiology, and Detection - March 2026The Points of CARE - James Gavin & Naunihal Virdi on CGM Use in Noninsulin-Treated Patients, Ivy Shi & Dhruv Kazi on GLP-1 RA Eligibility in Reproductive-Age US Women, and Eva Tseng on START Diabetes PreventionSpecial Edition: What's Next—Emerging Technologies for People with DiabetesAssociations between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy, Tirzepetide vs. Dulaglutide or Semaglutide on major cardiovascular events in T2D, and more!Special Edition: What's Next—Once-Weekly InsulinSpecial Edition: What's Next—Cardiovascular Risk in CKD—The Overlooked BurdenSpecial Edition: What's Next—Cortisol, Metabolism & Future Innovation, Part 4
